In hospital costs of acute heart failure patients in the Czech Republic

• Authors: Barbora Ondrackova , Roman Miklik , Jiri Parenica , Jindrich Spinar , Michal Sticha , Alexandra Sulcova
• Languages of publication: EN

Abstracts

EN

The retrospective cost analysis estimates direct in-patient costs and length of stay (LOS) in hospital for acute heart failure (AHF). Patients were hospitalized with acute decompensation (ADHF) or de novo AHF in the Faculty Hospital Brno in 2005 and 2006. Burden incurred is divided to standard cardiology unit (SCU) and intensive care unit (ICU). In-patient care costs include flat rate of admission, stay and medicinal procedures. The pharmaceuticals are included in daily in-patient rate; angiography, revascularizations and antiarrhythmic interventions are calculated separately. In total, 734 patients (57% male, mean age 71.7 years) with AHF were analyzed. De novo AHF (58.6%) was more common than ADHF; according to the clinical classification AHF with mild signs and symptoms prevailed (46%). The overall direct hospital cost of all patients was €2.4 million, mean LOS was 8.3 days and mean in-patient cost was €3295 (including all interventions). Almost a half passed through both SCU and ICU with LOS 10.8 days; mean LOS in the SCU was 8.3 days with one-day cost of €55; mean LOS in the ICU was 3.4 days with one-day cost of €618. Total cost of cardiac catheterizations and revascularizations (50% patients) was almost a million; cost of antiarrhythmic interventions was €529216 (implantation of pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy with biventricular device; 6.9% patients). Mortality during hospitalization was 14.6%. AHF is associated with poor prognosis and high costs during hospital admission; the predominant contributors of high costs are revascularization procedures (39%), stay in the ICU (31%) and antiarrhythmic interventions (22%).

Keywords

EN

Acute heart failure; Cost analysis; Health economy; Direct in-hospital costs; Czech Republic

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 4
• Pages: 483-489

Dates

published

1 - 12 - 2009

online

3 - 10 - 2009

Contributors

author

Barbora Ondrackova

• Department of Pharmacology, Faculty of Medicine, Masaryk University, 66243, Brno, Czech Republic

author

Roman Miklik

• Department of Internal Cardiology, Faculty Hospital Brno, 62500, Brno, Czech Republic

author

Jiri Parenica

• Department of Internal Cardiology, Faculty Hospital Brno, 62500, Brno, Czech Republic

author

Jindrich Spinar

• Department of Internal Cardiology, Faculty Hospital Brno, 62500, Brno, Czech Republic

author

Michal Sticha

• Institute of Biostatistics and Analyses, Faculty of Science & Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic

author

Alexandra Sulcova

• Department of Pharmacology, Faculty of Medicine, Masaryk University, 66243, Brno, Czech Republic

References

• [1] The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005;26(11):1115–1140. [PubMed]
• [2] Spac J. Lecba chronickeho srdecního selhani u starsich nemocnych. (Chronic heart failure treatment in elderly). Medicina po promoci 2006;6:56.
• [3] Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208–225. [Crossref][PubMed]
• [4] The Task Force on Acute Heart Failure for the European Society of Cardiology. Executive summary of the guidelines on the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:384–416.
• [5] Spinar J, Jansky P, Kettner J, Malek I. Doporuceni pro diagnostiku a lecbu akutniho srdecniho selhani. (Recommendations for diagnosis and treatment of acute heart failure). Cor Vasa 2006;48:K3–K31.
• [6] Spinar J, Spinarova L, Vitovec J. The diagnosis, epidemiology, and prognosis of acute heart failure. Cor Vasa 2008;50 (4):171–175.
• [7] Spinar J, Malek I. Lecba akutniho srdecniho selhani. (Managing acute heart failure). Cor Vasa 2008;50(4):177–182.
• [8] Spinar J, Aschermann M, Al-Hiti H, Belohlavek J, Dusek L, Hlinomaz O, Kettner J, Linhart A, Malek I, Miklik R, Novak M, Parenica J, Vitovec J. Acute heart failure databases in specialist departments of cardiology. Cor Vasa 2008;50(1):12–21.
• [9] Czech National Bank. Available from: http://www.cnb.cz
• [10] Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;6:693–700.
• [11] European Central Bank. ECB reference exchange rate, US dollar/Euro, 2:15 pm (C.E.T.). Available from: http://sdw.ecb.europa.eu/quickview.do?SERIES_KEY=120.EXR.D.USD.EUR.SP00.A
• [12] de Lissovoy G, Fraeman K, Mullahy J, et al. Hospital costs for treatment of acute heart failure: Economic analysis of Revive II study. Proceedings of the ISPOR 10th Annual European Congress; 2007 Oct 20–23; Dublin. Ireland: Value Health 2007;10(6):A412.
• [13] de Lissovoy G, Fraeman K, Sterz R. Resource Use and Treatment Costs for Acute Decompensated Heart Failure: Economic Analysis of the SURVIVE Trial. Proceedings of the ISPOR 10th Annual European Congress; 2007 Oct 20–23; Dublin. Ireland: Value Health 2007;10(6):A415.
• [14] Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725–2736. http://dx.doi.org/10.1093/eurheartj/ehl193[Crossref]
• [15] Siirila-Waris K, Lassus J, Melin J, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006;27:3011–3017. http://dx.doi.org/10.1093/eurheartj/ehl407
• [16] Institute of Health Information and Statistics of the Czech Republic. Deaths 2005. Available from: http://www.uzis.cz [Accessed November 30, 2006].
• [17] Institute of Health Information and Statistics of the Czech Republic. Czech Health Statistics Yearbook 2005. Available from: http://www.uzis.cz [Accessed December 4, 2006].
• [18] Institute of Health Information and Statistics of the Czech Republic. Czech Health Statistics Yearbook 2006. Available from: http://www.uzis.cz [Accessed November 15, 2007].
• [19] McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596–602. http://dx.doi.org/10.1136/heart.83.5.596[Crossref]
• [20] Berry C, Murdoch DR, McMurray JJV. Economics of chronic heart failure. Eur J Heart Fail 2001;3:283–291. http://dx.doi.org/10.1016/S1388-9842(01)00123-4[Crossref]
• [21] Haycox A, Bagust A. Pharmacoeconomics and clinical trials. In Walley T, Haycox A, Boland A. Pharmacoeconomics. Churchill Livingstone, Elsevier Science Limited, 2004. 203p. ISBN 0443 07240 X

Identifiers

DOI

10.2478/s11536-009-0056-z